《大行報告》大摩下調中國中免(01880.HK)目標價至200元 評級「增持」
大摩發表報告指,在8、9月期間,新冠疫情反彈導致在海南線下銷售被中斷的時間較長,即使部分被較高的線上銷售所抵銷,但較高的線上銷售組合和美元升值或拖累利潤率,該行預料,公司第三季的收入和淨利潤按年分別降31%及73%,並料今年全年收入和盈利分別降17%及18%。
該行表示,在10月初,疫情反覆和防疫措施收緊,或拖累旅遊和消費的復甦,該行對公司明年透過網絡擴張,以獲取更多市場份額,持建設性態度。該行降其2023至2024年收入預測介乎7%至8%,每股盈測降介乎8%至10%;相應將其H股目標價由215元下調至200元,維持其評級為「增持」。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.